Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Lowered to $81.00 at Raymond James

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) had its target price trimmed by Raymond James from $83.00 to $81.00 in a research report sent to investors on Thursday morning, The Fly reports. Several other analysts also recently commented on the stock. HC Wainwright reissued a buy rating and set a $61.00 price objective on shares of […]

Related Keywords

Christopher Peetz ,Raymond James ,Niall Odonnel ,Mirum Pharmaceuticals Inc ,Victory Capital Management Inc ,News Ratings For Mirum Pharmaceuticals Daily ,Jacobs Levy Equity Management Inc ,Mirum Pharmaceuticals ,Mirum Pharmaceuticals Company Profile ,Eventide Asset Management ,Nasdaq ,Russell Investments Group Ltd ,Mirum Pharmaceuticals Price Performance ,Get Rating ,Investments Group ,Levy Equity Management ,Asset Management ,Capital Management ,Prosight Management ,Niallo Donnel ,Michael Grey ,Foster City ,Mirum Pharmaceuticals Daily ,Nasdaq Mirm ,Smirm ,Medical ,Lower Price Target ,